The Hematologic Malignancies Program (HMP) was established in 1995 as the Stem Cell Biology and Therapeutics Program. It was given its present name in 2004 to better reflect the overarching mission of the HMP, i.e. to translate basic scientific discoveries into novel therapeutics for patients with myeloid and lymphoid neoplasms. To support this mission, the HMP has 5 scientific goals. These are to: 1) develop a mechanistic understanding of the role of chromosomal translocations, chromatin remodeling, and transcription factors in regulating normal and malignant hematopoiesis;2) define the receptors and signal transduction pathways employed by malignant hematopoietic cells to respond to specific environmental stimuli;3) investigate the immune response to these cells to develop more effective immune-based therapies;4) create animal models to test promising discoveries coming from the laboratory;and 5) design and conduct innovative, field-leading clinical trials. The Program has been led for the past decade by Alan M. Gewirtz, MD, a pioneer of translational research in the hematologic malignancies. Dr. Edward Stadtmauer, a leader in clinical trials of novel therapeutics for hematologic malignancies and bone marrow transplantation, has served as Co-Leader for the past 2 years. The HMP has 19 primary members, drawn from 5 Departments (Medicine, Pediatrics, Genetics, Pathology, Cancer Cell Biology) within the University of Pennsylvania School of Medicine, who share a strong research interest in the molecular, cellular, structural, biochemical and immunological approaches to understanding blood cancers and their treatment. HMP member interactions are facilitated by common use of Cores, multiple weekly seminars and meetings, collaborative grant submissions, and an annual research retreat. During the last budget period, a total of 38 peer reviewed projects were supported by NCI, NIH, and other non-governmental agencies (LLS, ACS) for a total of $5,693,859 in research funding (annual direct costs) of which $4,927,175 is peer-reviewed and $2,652,239 is from the NCI. During the last review period, HMP members published 333 cancer-related papers. Of these, 13% were intra-programmatic collaborations and 42% resulted from inter-programmatic collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016520-38
Application #
8593257
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$117,845
Indirect Cost
$86,401
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Qin, Jie; Rajaratnam, Rajathees; Feng, Li et al. (2015) Development of organometallic S6K1 inhibitors. J Med Chem 58:305-14
Al Zaki, Ajlan; Joh, Daniel; Cheng, Zhiliang et al. (2014) Gold-loaded polymeric micelles for computed tomography-guided radiation therapy treatment and radiosensitization. ACS Nano 8:104-12
Couch, Fergus J; Nathanson, Katherine L; Offit, Kenneth (2014) Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science 343:1466-70
Maus, Marcela V; June, Carl H (2014) CARTs on the road for myeloma. Clin Cancer Res 20:3899-901
Mays, Lauren E; Wang, Lili; Lin, Jianping et al. (2014) AAV8 induces tolerance in murine muscle as a result of poor APC transduction, T cell exhaustion, and minimal MHCI upregulation on target cells. Mol Ther 22:28-41
Noti, Mario; Kim, Brian S; Siracusa, Mark C et al. (2014) Exposure to food allergens through inflamed skin promotes intestinal food allergy through the thymic stromal lymphopoietin-basophil axis. J Allergy Clin Immunol 133:1390-9, 1399.e1-6
Rosenfeld, Myrna R; Ye, Xiaobu; Supko, Jeffrey G et al. (2014) A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 10:1359-68
Seth, Asha; Ye, Jianming; Yu, Nanjia et al. (2014) Prox1 ablation in hepatic progenitors causes defective hepatocyte specification and increases biliary cell commitment. Development 141:538-47
Zhang, Liming; Zhu, Caixia; Guo, Yi et al. (2014) Inhibition of KAP1 enhances hypoxia-induced Kaposi's sarcoma-associated herpesvirus reactivation through RBP-J?. J Virol 88:6873-84
Bhattacharya, Sabyasachi; Katlinski, Kanstantsin V; Reichert, Maximilian et al. (2014) Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol Med 6:384-97

Showing the most recent 10 out of 193 publications